Zenas BioPharma Inc. and Bicara Therapeutics Inc. on Friday both set estimated price ranges in their initial public offerings in a sign that the traditional summer lull in deals is coming to an end.
More Stories
Bank stocks join market rally. Analyst cites boost to lenders’ balance sheets.
Bank stocks moved up on Thursday as they added to gains from the previous session on the heels of the...
These tips for investing in mutual funds and ETFs can help you ride with the Fed
Gold glitters, while investors face recession jitters.
JetBlue Airways to open its first premium customer lounges in New York and Boston
Airline said it is responding to growing demand for “premium” perks.
Mobileye’s stock surges as Intel gives this reassuring sign
Mobileye and Intel shares have both been under heavy pressure this year, but Intel says it has no current plans...
Home sales fall to lowest level since October 2023
Existing-home sales fell to a rate of 3.86 million in August, the National Association of Realtors said.
Leading index for U.S. economy drops for sixth straight month in August
The leading indicators for the U.S. economy sank 0.2% in August, the privately run Conference Board said Thursday. That is...